Medicare Coverage For Lilly’s Tirzepatide Could Be ‘Unlocked’ With Heart Failure, Apnea Claims

The problem that obesity drugs are not covered by Medicare Part D might be alleviated if Lilly’s weight loss candidate is also cleared for indications that are reimbursed. Policy and treatment experts discuss the importance of proving obesity drugs can lower federal government health care spending during a recent discussion convened by the Institute for Clinical and Economic Review.